Chemical Linkers in Antibody-Drug Conjugates (ADCs) Editors: Floris van Delft, John M. Lambert


Publication details

Print publication date
22 Dec 2021
Copyright year
2022
Print ISBN
978-1-83916-263-3
PDF eISBN
978-1-83916-515-3
ePub eISBN
978-1-83916-516-0

About this book

The covalent conjugation of potent cytotoxic agents to monoclonal antibodies, known as antibody-drug conjugates (ADCs) is a powerful approach in the field of targeted treatment of cancer. Clearly, both monoclonal antibody and cytotoxic payload are crucial elements in determining the clinical value of an ADC and have receive ample attention. However, the structural element connecting the two –the chemical linker– also plays an essential role in mode-of-action, efficacy, pharmacokinetics and safety profile of an ADC, but is often underappreciated in considerations of ADC design.

Chemical Linkers in Antibody–Drug Conjugates

aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody ratio, for stability, for release mechanism of payload, for pharmacokinetics, for stability determination, and for efficacy and safety. Ideal for postgraduate students and active researchers in drug discovery and development, this book provides a comprehensive description of linkers used in ADCs (clinical and late preclinical), insight into key quality attributes of linkers for ADCs, and aids the reader in understanding the role of linker chemistry and designing new ADCs.

From the book series:
Drug Discovery